Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call Transcript

Talat Imran: Sure. So as I mentioned in the past, we’re working on a sustained release formulation. This is the technology that’s going into our RT-110 PTH for hypoparathyroidism program. We have made considerable progress, which is why it’s in our roadmap for Phase 1. And that same approach is what we’re going to be working on this year with our RT-101 formulation to reformulate it into a long acting so that it’s more competitive with — like a Sandostatin LAR. So nothing to report at this moment in time, but I think that’s something that we’ll revisit later this year.

Mitchell Kapoor: Okay, great. Thank you very much.

Talat Imran: Thank you.

Operator: Thank you. I’m showing no further questions in the queue. I would now like to turn the call back to Talat for closing remarks.

Talat Imran: Thank you, operator. This concludes our fourth quarter and full year 2022 financial results and corporate update conference call. Thank you again everyone for joining us this afternoon.

Operator: Ladies and gentlemen, this concludes today’s conference call. Thank you for your participation. You may now disconnect.